[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation].
Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year. The results have shown that therapy with acenocumarol lowers content of D-dimer, prevents formation and promotes lysis of left auricular thrombi and lowers risk of development of ischemic stroke in patients with atrial fibrillation and high risk of thromboembolism. Therapy with aspirin in a dose providing maximal suppression of platelet function, does not lower D-dimer levels, does not promote lysis of left auricular thrombi and is inferior to acenocumarol in prevention of ischemic stroke.
Zharkova
T V
TV
Ataullakhanova
D M
DM
Bykova
E S
ES
Kropacheva
E S
ES
Dobrovol'skiĭ
A B
AB
Titaeva
E V
EV
Panchenko
E P
EP
D000074:Acenocoumarol / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count; D013922:Thrombocytosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013927:Thrombosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D000074:Acenocoumarol; D001241:Aspirin